Article ; Online: Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review.
2018 Volume 51, Issue 8, Page(s) e7440
Abstract: ... findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis ... in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive ... Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple ...
Abstract | Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies. |
---|---|
MeSH term(s) | Animals ; Arthralgia/drug therapy ; Bone Density Conservation Agents/pharmacology ; Bone Density Conservation Agents/therapeutic use ; Bone Remodeling/drug effects ; Bone Resorption/drug therapy ; Cartilage, Articular/drug effects ; Disease Progression ; Humans ; Osteoarthritis/drug therapy ; Thiophenes/pharmacology ; Thiophenes/therapeutic use |
Chemical Substances | Bone Density Conservation Agents ; Thiophenes ; strontium ranelate (04NQ160FRU) |
Language | English |
Publishing date | 2018-06-18 |
Publishing country | Brazil |
Document type | Journal Article ; Review ; Systematic Review |
ZDB-ID | 786234-9 |
ISSN | 1414-431X ; 0100-879X |
ISSN (online) | 1414-431X |
ISSN | 0100-879X |
DOI | 10.1590/1414-431x20187440 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 1359: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.